Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer: One institution’s experience

Table 1 Baseline clinical and pathological characteristics of the patients n (%)

Characteristic	MSG (n = 157)	CG (n = 196)
Gender
Male	104 (66.2)	137 (69.9)
Female	53 (33.8)	59 (30.1)
Age
< 60 yr	87 (55.4)	110 (56.1)
60-69 yr	54 (34.4)	67 (34.2)
70-80 yr	16 (10.2)	19 (9.7)
Median year	58	62
Range year	29-80	31-78
Cancer stage, TNM classification
IB	3 (1.9)	4 (2.0)
II	85 (54.1)	103 (52.6)
III	54 (34.4)	71 (36.2)
IV	15 (9.6)	18 (9.2)
Histologic type
Differentiated	73 (46.5)	103 (52.6)
Undifferentiated	84 (53.5)	93 (47.4)

Table 2 Severe adverse effects and toxicities (NCI-CTC version 2.0)

Toxicities	MSG (n = 157)			CG (n = 196)
	Grade III (No.)	Grade IV (No.)	Grade III/IV (%)	Grade III (No.)	Grade IV (No.)	Grade III/IV (%)
Hematologic toxicity
Leukopenia	2	2	2.5	4	1	2.6
Anemia	2	0	1.3	2	2	2.0
Thrombocytopenia	0	0	0.0	1	0	0.5
Non-hematologic toxicity
Diarrhea	2	0	1.3	3	0	1.5
Stomatitis	1	0	0.6	0	0	0.0
Nausea	2	1	2.5	2	0	1.0
Vomiting	2	0	1.3	3	0	1.5
Anorexia	8	2	6.4	6	3	4.6
Fever	0	0	0.0	2	0	1.0
Rash	1	0	0.6	1	0	0.5
Elevated aminotransferase	2	0	1.3	3	1	2.0
Hyperbilirubinemia	1	0	0.6	2	0	1.0
Elevated creatinine	0	0	0.0	1	0	0.5